Introduction {#s1}
============

Otitis media (OM) is one of the most common childhood diseases. With prevalence reaching as high as 5,000,000 annually in the United States, OM is a leading cause for pediatrician office visits and antibiotic prescriptions each year ([@B57]). The associated medical expenditures account for as high as \$4.1 billion, contributing to a significant healthcare utilization burden for both the healthcare system and patients ([@B39]; [@B16]; [@B32]; [@B1]; [@B57]). OM primarily affects children between the ages of 6 and 24 months, with 80--90% infants likely to experience OM disease at least once before reaching school age despite the introduction of the heptavalent pneumococcal conjugate vaccine in 2000 and its tri-decavalent counterpart in 2010 ([@B86]; [@B46]; [@B56]; [@B57]). With resistance to standard antibiotic treatment continuing to increase steadily, the need for a more comprehensive understanding of OM pathogenesis and potential treatment modalities has become an immediate priority for pediatric and otolaryngology clinicians.

The specific diagnostic classification of OM varies according to its clinical presentation, which is characterized by specific signs and symptoms, disease progression, and the effectiveness of treatment. OM can be classified as acute otitis media (AOM) or otitis media with effusion (OME) when findings include an accumulation of fluid (middle ear effusion) behind the tympanic membrane ([@B46]; [@B97]). According to the latest guidelines, a diagnosis of AOM requires a moderate to severe bulging of the tympanic membrane, otorrhea, and ear pain with erythema; in contrast, these symptoms are often absent in OME ([@B72]; [@B100]). When AOM/OME persists despite treatment with antibiotics and/or surgical methods, chronic otitis media (COM), chronic otitis media with effusion (COME), or chronic suppurative otitis media (CSOM) may be indicated. COM is defined as recurrent infection of the middle ear with dry tympanic membrane perforation. COME shares a similar clinical presentation but with the addition of continuous serous drainage, while CSOM features purulent drainage leaking from a perforated tympanic membrane or ventilation tube ([@B78]; [@B97]). Chronic OM etiologies tend to be more serious for patients, as frequent and/or persistent dysfunction of the Eustachian tube may lead to significant hearing loss, thereby negatively impacting language acquisition and behavioral development in children ([@B33]; [@B95]; [@B112]).

In many clinical cases, the manifestations of OM may overlap and co-occur. Therefore, the diagnostic distinctions between the many OM etiologies are important as they help in determining the adequate course of treatment and expected duration of disease. Some physicians utilize watchful waiting even with diagnosed OM cases to allow for the activation and response of the patient's immune response that may help in the clearance of infection. Symptomatic therapy is indicated in the vast majority of OM cases, with antibiotic treatment regimens only appropriate when cases are persistent. Surgical methods such as tympanostomy tube or grommet insertion are implemented when case recurrence is especially severe ([@B85]; [@B59]). Beyond guiding treatment, however, diagnostic classifications have also been linked to particular offending pathogenic microorganisms despite the fact that obtaining a culture-confirmed diagnosis is not routine in the clinical setting. *Streptococcus pneumoniae*, non-typeable *Haemophilus influenzae* (NTHi), and *Moraxella catarrhalis* are the three main otopathogens known to cause AOM worldwide ([@B19]; [@B20]; [@B57]; [@B67]). International epidemiological studies of Latin American and Caribbean populations have also confirmed *S. pneumoniae* and NTHi as the most frequent AOM bacterial pathogens ([@B6]). In addition to these known and culturable otopathogens, a growing body of research has helped highlight how other bacterial, fungal, and/or viral species differentially contribute to the pathogenesis of various OM subtypes ([@B29]; [@B83]; [@B30]). For example, clinical and animal studies both demonstrate how inflammation and microbiome disruption of an initial viral and/or bacterial infection of the upper respiratory tract often contributes to the pathogenesis of AOM ([@B32]; [@B97]; [@B35]). Progression of AOM to COM is largely believed to be due to the complex interactions between bacterial, environmental, and host factors. *Pseudomonas aeruginosa* and *Staphylococcus aureus* ([@B78]; [@B80]) are the most common pathogens associated with CSOM. However, our current knowledge about COM, especially CSOM, is still very limited and further studies are warranted to understand the pathogenesis of disease.

Early studies attempted to identify the microbiological causes of OM that were limited to culturable bacteria. However, the expansion of 16S ribosomal RNA (rRNA) sequencing and other culture-independent methods have allowed for the identification of microorganisms within the nasopharynx (NP) and middle ear (ME) that play an important role in both resident microbiota and intruding pathogenic populations ([@B17]; [@B87]; [@B54]). The advancement of these bioinformatic and genomic detection methods have allowed researchers to incorporate insights from the host genome and microbiome that have both deepened and complicated our knowledge of OM pathogenesis. Decades of research have helped uncover links between host genes and OM susceptibility, but our expanding repository of microbiome literature across many fields has introduced new questions regarding the host microbiota's role in pathogenesis, progression, and persistence of many disease etiologies. For instance, recent studies exploring the interplay between individual genes and microbiome composition in the gastrointestinal system, such as the gene-microbe interaction found to drive the development of Crohn's disease-like colitis in mice, suggesting the potential of this interdisciplinary approach for future OM research ([@B18]). The goal is that these insights will lead to the development of novel treatment modalities such as probiotic therapies, thereby addressing concerns of growing antibiotic resistance amidst continuously high OM disease burden ([@B67]; [@B79]). In this article, we describe the recent developments in OM research that elucidate the interactions between host genes, microbiome composition, and OM pathogenesis, and we identify relevant gaps in understanding that should we believe should be prioritized in future research.

Genetics of Otitis Media {#s1_1}
------------------------

### Twin Studies {#s1_1_1}

The first studies to assess the role of genetics in acquiring recurrent OM were mainly twin studies ([**Table 1**](#T1){ref-type="table"}). One of these initial studies was a retrospective study comprising of 2,750 pairs of Norwegian twins born between 1967 and 1974 ([@B63]). A series of eight structural equation models were constructed to estimate genetic effects, individual environmental effects, common familial environment effects in males, and dominance effects in females on the predisposition to develop OM ([@B63]). After selecting a model that best fit the data, it was found that heritability of OM was estimated at 45 and 75% in males and females, respectively ([@B63]). It is important to note that, despite common misinterpretation, these heritability values do not suggest that OM is 45 or 75% caused by genetics. Instead, the heritability values suggest that 45 and 75% of the variability in developing OM can be attributed to genetic differences in the populations studied. Twin studies are vital in guiding further scientific research to study the role of genetics in OM. A few other important twin studies are described below.

###### 

Significant heritability values from various twin and triplet studies.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Heritability    Ages affected   Case definition                                                                                                                                                                                                          Reference
  --------------- --------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -----------
  Males: 0.45\    0--7            Individuals with recurrent ear infections before 7 years old                                                                                                                                                             [@B63]
  Females: 0.75                                                                                                                                                                                                                                            

  0.73            0--2            AOM: presence of effusion, at least one symptom (fever, otalgia, or irritability), and one sign of inflammation (erythema, bulging/fullness, or otorrhea) OME: presence of middle ear effusion without symptoms of AOM   [@B21]

  0.72            0--5            AOM: presence of effusion, at least one symptom (fever, otalgia, or irritability), and one sign of inflammation (erythema, bulging/fullness, or otorrhea) OME: presence of middle ear effusion without symptoms of AOM   [@B22]

  0.57            0--4            OM: earache, ears leaking pus/mucus, pulling or scratching ears, and red or sore ears                                                                                                                                    [@B89]
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Another study, a prospective twin and triplet study, investigated the genetic component of recurrent ME effusion and AOM ([@B21]) ([**Table 1**](#T1){ref-type="table"}). From 1982 to 1995, 168 same-sex twin pairs and 7 same-sex triplet sets younger than 2 months old were recruited for the study mainly from Magee-Women's Hospital in Pittsburgh, PA ([@B21]). Only same-sex twin and triplet sets were included in the study due to differences in incidence of OM between males and females. From the 168 twin and triplet sets first recruited, 126 were followed for 2 years and any episodes of ME effusion or AOM were documented. From these 126 twin and triplet sets, the estimated degrees of discordance for three or more episodes of ME effusion were 0.04 and 0.37 for monozygotic and dizygotic twins, respectively. For an episode of AOM, the estimates of discordance were 0.04 in monozygotic twins and 0.49 in dizygotic twins. These discordance values imply that monozygotic twins shared similar presence of illness compared to dizygotic twins, who did not become ill in conjunction with each other as often. These results suggest genetics play some role in susceptibility of the illness since monozygotic twins showed more concordance with disease than dizygotic twins. Lastly, the heritability of recurrent ME effusion was estimated at 0.73 after 2 years, which suggests genetics plays a significant role in the individual variation of OM cases. In 1987, researchers altered the protocol to extend the follow-up period to 5 years ([@B22]). Eighty-three sets of twins or triplets were followed for 5 years, and the heritability of recurrent ME effusion within 5 years of life was estimated at 0.72, further suggesting genetics may play a large role in susceptibility to OM ([@B22]).

To further understand the extent of genetic predisposition for OM, the Twin Early Development Study, a longitudinal study of same-sex twins born in England and Wales in 1994, was conducted ([@B89]). Unlike previous studies, this study set out to estimate the heritability of different manifestations and symptoms of OM compared to those of chronic airway blockage, which frequently accompanies persistent effusion ([@B89]). The researchers followed 1,373 twin pairs for 2, 3, and 4 years, assessing the occurrence of OM symptoms (earache, ears leaking pus or mucus, pulling or scratching ears, and red or sore ears) and chronic airway blockage symptoms (breathing through the mouth and snoring or snorting in sleep). When the OM and the chronic airway blockage symptoms were combined, the heritability was estimated at 0.49, 0.66, and 0.71 for ages 2, 3, and 4, respectively. When tested separately, the heritability of OM symptoms averaged over all years was estimated to be 0.57, and the effect of twin shared environment was 0.18. The chronic airway blockage symptoms when tested alone showed higher heritability (0.72) and a lower effect of twin shared environment (0.10) compared to those of OM. This investigation elucidates the importance of separating the symptoms of OM from those of chronic airway blockage instead of considering the two as undifferentiated OM.

As briefly mentioned before, these twin studies, although a good starting point for investigating the role of genetics in OM, provide minimal evidence compared to other studies of genetic causation or predisposition to developing OM. The main reason for the poor level of evidence is that a twin study only provides information about the role of genetics in the variation of the disease in a population. Heritability values cannot be used at the individual level to declare that a specific disease is caused by genetic factors some percentage of the time. The other issue with twin studies is that they provide no insight as to the specific genetic loci that may be implicated in OM, only a general sense of genetic heritability. It is important to note that the heritability measures are applicable/specific only to the cohort in which they are estimated.

Linkage Studies {#s1_2}
---------------

Besides twin investigations, there has been interest in investigating genetic determinants of chronic and recurrent OM across the entire genome using linkage studies ([@B34]) ([**Table 2**](#T2){ref-type="table"}). In a linkage analysis, researchers assess the statistical linkage of segments of the genome with the phenotype of interest among a series of families. One study recruited individuals who received tympanostomy tube surgery to treat chronic or recurrent OM and their families ([@B34]). From 133 families, they acquired 591 DNA samples, 238 of which were affected by chronic or recurrent OM, for genetic screening. The DNA samples were then screened for 404 fluorescent microsatellite markers and analyzed by single- and multipoint nonparametric linkage (NPL). The single-point NPL analyses suggested significant evidence of linkage on chromosome 10q26.3 at marker *D10S212* (LOD 3.78) and suggestive evidence of linkage on chromosome 19q13.43 at marker *D19S254* (LOD 2.61). The multipoint NPL analyses suggested strong evidence of linkage on chromosome 19q near marker *D19S254* (LOD 2.53). Interestingly, the multipoint NPL analyses showed decreased linkage on chromosome 10q near marker *D10S212* (LOD 1.64). Conditional analyses were then performed on samples that supported linkage on 10q and 19q in order to potentially increase other significant regions of the genome ([@B34]). The conditional analyses revealed linkage for chronic or recurrent OM on a region of chromosome 3p \[conditional (10q) LOD 2.43; conditional (19q) LOD 1.84; unconditional LOD 0.60\]. These analyses suggest that there exists an interaction between several regions of the genome that plays a role in the risk of chronic or recurrent OM.

###### 

List of chromosomes implicated in otitis media based on various nonparametric linkage analyses.

  Chromosome         LOD score   Marker           Case definition                                                                                                                                                                                                                                                      Reference
  ------------------ ----------- ---------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------
  **10q26.3^\*^**    3.78        *D10S212*        At least two data sources indicated positive results for ear examination, tympanogram, self-reported history, and/or medical record OR 1 data source indicated positive results for above findings and current middle-ear findings presumptive of COME/ROM history   [@B34]
  **19q13.43^\*^**   2.61        *D19S254*                                                                                                                                                                                                                                                                             
  **19q**            2.53        Near *D19S254*                                                                                                                                                                                                                                                                        
  **10q**            1.64        Near *D10S212*                                                                                                                                                                                                                                                                        
  **3p^a^**          2.43        NA                                                                                                                                                                                                                                                                                    
  **3p^b^**          1.84        NA                                                                                                                                                                                                                                                                                    
  **3p^c^**          0.6         NA                                                                                                                                                                                                                                                                                    
  **17q12**          2.83        NA               Insertion of tympanostomy tube at least once for recurrent/persistent OM                                                                                                                                                                                             [@B23]
  **6p25.1**         2.25        NA                                                                                                                                                                                                                                                                                    
  **19**             3.75        63.4 mb          Tympanostomy tube insertion for COME/ROM, presence of OM sequelae, and/or abnormal middle ear mechanics                                                                                                                                                              [@B26]

\*Single-point nonparametric linkage (NPL) analyses; all other linkages found from multipoint NPL analyses. ^a^Conditional analysis with 10q. ^b^Conditional analysis with 19q. ^c^Unconditional analysis (not significant). NA, not analyzed.

Another study also attempted a linkage analysis to further identify possible genes that increase the risk of OM ([@B23]). The researchers recruited families with two or more full siblings who received tympanostomy tube insertions due to a history of OM. Four hundred and three Caucasian families (1,431 individuals) and 26 African American families (75 individuals) were genotyped. The researchers carried out an NPL analysis using 8,802 single-nucleotide polymorphisms (SNPs) on the larger Caucasian data set, at first by itself and then in conjunction with the African American data set. When analyzed by itself, the Caucasian data set suggested strong linkage on chromosome 17q12 (LOD 2.83) and 6p25.1 (LOD 2.25). There were also three other suggestive linkages on 10q22.3, 7q33, and 4p15.2, but these were not as significant as the linkage on 17q12. When the data sets were combined, the peaks on chromosomes 17, 6, and 4 became less significant, but the linkage on chromosome 10q22.3 became more significant. The authors also suggest that these linkage signals are near previously implicated genes *SFTPA2*, *IFNG*, and *TNF* ([@B23]).

To further localize significant linkage signals, another study set out to fine map chromosome 19, the chromosome previously implicated in [@B34] ([@B26]). The researchers recruited individuals who received tympanostomy tube surgery to treat chronic or recurrent OM and their families. The participants included all subjects from the initial study and an additional six new families (a total of 607 individuals from 139 families). The researchers performed an NPL analysis of 1,091 SNPs, the majority of them were from chromosome 19. The NPL analysis suggested significant linkage on chromosome 19 at position 63.4 mb (LOD 3.75) with LOD-1 support interval between 61.6 and 63.8 mb. This region of the genome contains over 90 known genes and includes several genes implicated in inflammatory and immune processes ([@B26]).

These linkage analysis studies were large leaps forward in illustrating the potential genetics of OM because they isolated specific genomic sequences that statistically linked with cases of OM. Despite these promising findings, though, linkage analysis has its limitations. In linkage analysis, there can be a significant increase in the rate of false positives and a reduction of statistical power ([@B37]). Therefore the results of linkage studies should be evaluated with caution. In an attempt to overcome the drawbacks of linkage analysis studies, researchers focused their efforts in candidate gene approach studies to test the statistical association between specific genes and/or markers implicated in OM from previous studies and cases of OM in a population.

Otitis Media in Mouse Models {#s1_3}
----------------------------

The mouse model is a useful tool to study and identify the genes relevant to OM. There are genes that are essential for the maintenance of the ME epithelial cell integrity and health and mutations/deletion in these genes can determine predisposition to OM: 1) *Tgif1*---it functions as a negative regulator of the transforming growth factor beta (TGFβ) signaling pathway. *Tgif1* mutant mice have significantly raised auditory thresholds due to a conductive deafness arising from OM ([@B104]). 2) *Phex*---the mutation in the *Phex* gene primarily upregulates the expression level of the *Fgf23* gene in the MEs and is linked to predisposition to OM in mice ([@B45]). *Fgf23* mutant mice have also been shown to have mixed hearing loss and ME malformation ([@B73]). 3) *Oxgr1*---the *Oxgr1* gene encodes oxoglutarate receptor 1. The ligand for OXGR1 is believed to be involved in the regulation of vascular endothelial growth factor, an important inducer of angiogenesis and vascular permeability. [@B58] showed presence of inflammatory cells, changes in the mucosal epithelium, and ME fluid in *Oxgr1* deficient mice. 4) *Mcph1*---the *Mcph1*-deficient mice had mild to moderate hearing loss (around 70% penetrance). Other defects of *Mcph1*-deficient mice included small skull sizes, increased micronuclei in red blood cells, increased B cells, and ocular abnormalities ([@B27]). 5) *Lmna*---*Lmna* mutant mice have profound early-onset hearing deficits and abnormal positioning of the Eustachian tube accompanied by OM ([@B118]).

There is also evidence of the involvement of signaling pathways and inflammatory factors involved in OM. *Pai-1* knockout mice showed significant pathological changes of tympanosclerosis ([@B99]); mice deficient in the *C5a* gene have been shown to have reduced levels of IL-6, mKC, and MCP-1, in association with decrease in inflammatory cell recruitment, mucosal inflammation, and bacterial clearance ([@B106]); mice lacking the *IL-17A* gene, encoding interleukin 17A (IL-17A), a neutrophil inducing factor, were associated with abnormal recruitment and apoptosis of neutrophils ([@B113]).

Mouse-To-Man Candidate Gene Study {#s1_4}
---------------------------------

All cohorts for OM reported thus far have low power to detect common genetic risk factors for disease and have low resolution. The specific genetic susceptibility loci for OM can be identified, however, through genome-wide or candidate gene association studies. Candidate gene studies can theoretically overcome these issues of low power and resolution by focusing directly on the association between disease and genetic variants with strong support for their involvement in the biology. Through candidate gene association studies, efforts have been made to test the association of chronic OM with specific genetic loci that have been identified as potential risk loci of OM in mouse models. In candidate gene studies, the frequencies of a genetic marker are compared between affected study subjects and control subjects. The control subjects can be unrelated healthy controls (case-control study) or healthy siblings or other family members (family study). But with the candidate gene approach, ascertaining relevant loci for testing can be difficult and thus are likely to miss many causal regions. Increasingly, genetically altered mouse models, such as those discussed earlier, have been used to study OM because of the technology available to genetically alter this species and translate the analysis of suspected genes to the human model.

[@B7] performed a genetic association study on a large cohort of children with COME, and tested SNPs at candidate loci derived from four genetically altered mouse models that have identified *Fbxo11*, *Evi1*, *Tgif1*, and *Nisch* as potential risk loci for chronic OM. Of the 1,296 families analyzed, evidence of association was found at rs881835 and rs1962914 at the *TGIF1* locus, with odds ratios of 1.4--1.6. There was a weaker association with rs10490302 and rs2537742, two SNPs within *FBXO11*, with odds ratios of around 1.2. All these SNPs are located in intronic regions. However, no evidence of association with the loci *EVI1* or *NISCH* was detected. Both the *TGIF1* and *FBXO11* loci are thought to be involved in TGF-β signaling, which implies that this pathway may be critical in the transition from acute to chronic ME inflammation. However, [@B7] reported that these results failed to replicate in a case-control cohort in Finland of 402 children with chronic OM with effusion and 777 control participants.

In previous studies, [@B90], in an analysis of 434 families predominantly suffering from recurrent AOM (p = 0.009) from Western Australia, showed an association with the major A allele at SNP rs330787 at *FBXO11*, with replication of this finding in an independent cohort (p = 6.9 × 10--6, OR = 1.55). [@B98] also reported nominal evidence of *association to the* SNP rs2134056 (p = 0.017) at *FBXO11* in their cohort of 142 families from the US (with a mixed OM phenotype). The *TGIF1* locus, found to be associated with risk of COME, has not been evaluated in any previous genetic association study. *EVI1* and *NISCH* were not associated with OM ([@B93]).

The data therefore indicate that regulation of the TGF-β pathway may be critical for the development of persistent inflammation in the ME. TGF-β has already been reported as a key regulator of inflammatory response, through its effects on chemotaxis, activation, and survival of lymphocytes, natural killer cells, dendritic cells, macrophages, mast cells, and granulocytes ([@B117]).

Other studies have attempted to isolate particular genetic loci associated with susceptibility to OM using a candidate gene association approach. What follows is a brief description of various other studies and their findings. A candidate gene study on 15 genes with single-nucleotide polymorphisms (SNPs) in 142 families with 618 subjects was conducted by [@B93]. Nominal genetic association was found for *MUC5AC* \[rs2735733, *P* = .002, odds ratio (OR) = 0.646; rs7396030, *P* = .049, OR = 1.565; rs2075859, *P* = .041, OR = 0.744\]. A trend toward association was also found in three other SNPs at three genes: *SCN1B* (rs810008, *P* = .013), *SFTPD* (rs1051246, *P* = .039), and *TLR4* (rs2770146, *P* = .038). [@B92] have shown functional evidence for a role for *SLC11A1* in susceptibility to OM and have studied the candidate gene in 660 affected children from 531 families in a case/pseudo-control study. The best SNP association was detected at the rs2776631 (*P* = .025). Furthermore, haplotype analysis revealed the 3_C\_C_G haplotype (rs34448891_rs2276631_rs3731865_rs2695343) to be more common in the affected individuals (*P* = .0008). [@B74], in a candidate gene study of 192 SNPs from eight genes on 100 cases and 79 controls, reported that 8 SNPs on four genes (*TLR4*, *MUC5B*, *SMAD2*, *SMAD4*) showed a potential trend toward association (*P* unadjusted = 0.007, rs10116253 on *TLR4*). It is important to note, though, that these eight SNPs did not show significant association after correcting for multiple statistical testing (*P* adjusted = 0.625, rs10116253 on TLR4). Also, an increased risk for OM proneness was found associated with the *CX3CR1* gene (Thr280Met, OR = 6.23, *P* = .038) in a study of 21 SNPs as risk factors for upper respiratory tract infections, OM, and OM proneness in 653 children ([@B82]). [@B49] conducted studies in a Greek cohort of 96 children on eight SNPs of five cytokine genes, that have demonstrated that *IL-10* (−592, −819, and −1082) and *TGF*β (codon 10C \> T) were associated with an increased number of acute OM episodes (*P* \< .001, *P* \< .001, *P* \< .001, and *P* = .002, respectively); *IL-10* (−1082) and *TGF*β (codon 10C \> T) were also associated with a later onset of AOM (*P* = .007 and *P* = .0039, respectively). [@B40] reported in 1,032 study subjects from Alaska that individuals homozygous for the arctic variant of *CPT1A* (c.1436C \> T) demonstrated a trend to more likely have OM (OR = 3.6, 95% confidence interval: 1.4--8.9). [@B43]performed a candidate gene study with 53 SNPs on 624 study subjects with recurrent acute OM and/or chronic OM with effusion and 778 control subjects. The positive result for *TLR4* (rs5030717, OR = 1.33, *P* = .003) was further investigated by a tagging SNP analysis and has resulted in the identification of two additional SNPs (rs1329060 and rs1329057). There was an increased association among patients with a more severe phenotype: those with OM starting before the age of 6 months (OR = 2.42, *P* = .0005, for rs1329060) and those with repeated insertions of tympanostomy tubes (OR = 1.65, *P* = .00004 for rs1329060). The finding was replicated in a Finnish OM cohort of 205 children (s1329060, OR = 1.32, *P* = .002; rs1329057, OR = 1.30, *P* = .003; rs5030717, OR = 1.34, *P* = .002). However, in three other cohorts (two in the United States and one in the United Kingdom), the three SNPs failed to show an association with the risk for OM. Finally, a variant, Asp299Gly (rs4986790) in *TLR4*, was found to be related to the colonization of *M. catarrhalis* in the upper respiratory tract of children (43%) in comparison with the *TLR4* wild type (9%) (RR = 4.91, P = .0001) ([@B43]).

Lastly, another large-scale candidate gene study investigated the role of *FUT2*, a gene whose protein product regulates the expression of red blood cell Lewis and ABO antigens and that had previously been associated with increased risk of recurrent urinary tract infections, in familial OM ([@B96]). For this study, families with children affected by OM were recruited. The participants were recruited from various ethnic backgrounds, including 137 individuals of indigenous Filipino descent ([@B94]), 257 trios of mother, father, and child from Texas, 76 individuals from Colorado, 140 families from a previous family cohort from the University of Minnesota ([@B93]), 105 families from Helsinki University Hospital ([@B42]), and 19 families from the southern Punjab province of Pakistan ([@B96]). This study suggests an association of the c.412C \> T variant of *FUT2* with chronic or recurrent OM in European-American children and family trios in the United States. Additionally, an association between the c.461G \> A variant and transmission in family trios in the United States as well as shifts in the microbiota composition in the ME were observed. Lastly, they reported an association of the c.604C \> T variant with OM in the Filipino data set, though 17 individuals did not show shifts in ME microbiota composition due to this variant. The authors proposed that *FUT2* variants confer higher risk for OM by modification of the microbiome in the ME. The authors also tested the expression and localization of *Fut2* and found that there is a transient increase in expression in the ME of mice inoculated with *H. influenzae* ([@B96]). This study's extensive array of results seems to suggest that different genetic variants and environmental factors influence susceptibility to OM ([@B96]).

These candidate gene association studies have moved the field forward by suggesting an association between OM susceptibility and these various genetic variants, but unfortunately the statistical power of these studies remains quite low. Up to now, most existing association studies in OM have been poorly phenotyped and used small sample sizes ([@B8]), which significantly reduces the statistical power, decreasing thus the probability of replication. The latter can also be due to variation in study design, particularly if phenotypes are poorly matched. For example, there is some evidence suggesting that chronic OM should be evaluated and analyzed as distinct from acute OM. Yet, many studies on genetic risk of chronic OM have used candidate loci involved in innate or acute inflammatory pathways and included cases of both recurrent acute and chronic OM. Furthermore, epidemiological studies have demonstrated that AOM is a risk factor for ME effusion, although many children with COME have no preceding history of AOM ([@B9]). Also, mouse transcript studies have shown that genes upregulated in the initial phase of inflammation are different to those found as inflammation resolves, suggesting that there is a molecular transition from acute to chronic inflammation ([@B47]). Other reasons for failure of replication may be that the genetic structure might be disparate ([@B66]), or that different pathogenic mechanisms exist in different populations.

Genome-Wide Association Studies {#s1_5}
-------------------------------

Since very few genes that contribute to the development of OM had been identified, genome-wide association studies (GWAS) have been used to decipher the genetic etiology of the disease by assessing whether any genetic variants throughout the entire genome associate with cases of OM ([**Table 3**](#T3){ref-type="table"}). A study recruited 416 cases (at least 3 episodes of AOM by the age of 3) and 1,075 controls from the Western Australian Pregnancy Cohort (Raine) Study, a longitudinal cohort study in Western Australia of 2,868 children whose mothers were recruited in early pregnancy from 1989 to 1991 ([@B91]). Despite a predominantly Caucasian cohort, it was reported that principle component analysis showed evidence for population stratification, or differences in allelic frequencies between subpopulations. The data set was corrected to account for this population substructure by adjusting for two principal components. Genome-wide association analysis of the corrected data set identified various SNPs showing association, the strongest of which were at *CAPN14* and *GALNT14* on chromosome 2p23.1. When the data set was tested without accounting for the population stratification, analysis did not reveal one significant genetic variant. Replication of the results was also attempted in a cohort of 793 affected individuals (55% with recurrent AOM and 45% with COM with effusion) from the Western Australian Family Study of OM. Twenty SNPs within seven candidate genes, including *CAPN14* and *GALNT14*, were genotyped, but no significant variants were identified. It was proposed that the lack of replication might be due to phenotypic and sample size differences in the populations ([@B91]). Another study attempted to replicate the results from the Western Australian Pregnancy Cohort (Raine) Study. Twenty-six autosomal SNPs from the Raine Study were analyzed for association in the sample of families with children affected by chronic OM with effusion and recurrent OM from the [@B34], study discussed previously ([@B3]). No significant association was found with any of the 26 SNPs tested; the p-values ranged from 0.03 to 0.93, never crossing the significance threshold of p = 0.001 ([@B3]).

###### 

List of genes implicated in otitis media from genomic association studies.

  Gene                 Allele or variant          Chromosome   Odds ratio, LOD score, or p-value        Case definition                                                                                                                                                                                                                 Reference
  -------------------- -------------------------- ------------ ---------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------
  *FBXO11*             A allele at rs10490302     2p16.3       OR 1.17                                  COME: symptomatic effusion for at least 3 months and effusion at operation                                                                                                                                                      [@B7]
                       G allele at rs2537742                   OR 1.16                                                                                                                                                                                                                                                                  
  *TGIF1*              T allele at rs881835       18p11.31     OR 1.39                                                                                                                                                                                                                                                                  
                       G allele at rs1962914                   OR 1.58                                                                                                                                                                                                                                                                  
  *FUT2*               c.412C \> T at rs1800022   19q13.33     p = 0.01\*                               Study assessed multiple different cohorts---case definition slightly different for each cohort                                                                                                                                  [@B96]
                       c.461G \> A at rs601338                 p = 0.01\*                                                                                                                                                                                                                                                               
                       c.604C \> T at rs1800028                LOD 4.0                                                                                                                                                                                                                                                                  
  *CAPN14*             rs6755194                  2p23.1       OR 1.90                                  Clinical exam within 3 years of life indicated presence of inflamed/retracted/scarred tympanic membrane, middle ear effusion, or tympanostomy tube OR parents reported 3 or more episodes of AOM within first 3 years of life   [@B91]
  *GALNT14*            rs1862981                               OR 1.60                                                                                                                                                                                                                                                                  
  *KIF7*               rs1110060                  15q26.1      p = 9.1 x 10^−7\ a^p = 0.072 ^b^         Insertion of tympanostomy tube at least once for recurrent/persistent OM                                                                                                                                                        [@B2]
  *CDCA7 and SP3^d^*   rs10497394                 2q31.1       p = 2.9 x 10^−5\ a^p = 4.7 x 10^−5b^                                                                                                                                                                                                                                     
  *FNDC1*              rs2932989                  6q25.3       p = 4.36 x 10^−8\ a^p = 2.15 x 10^−9c^   CHOP cohort: AOM defined using ICD-9 codes Generation R Study cohort: survey data on OM, otorrhea, fever with earache, and/or use of ear drops per subscription                                                                 [@B111]

\*Transmission disequilibrium test. ^a^Initial data. ^b^Replication data. ^c^Combined meta-analysis of initial and replication data. ^d^These genes border the corresponding marker, rs10497394.

A second GWAS study attempted to elucidate potential genes by genotyping 229 controls and 373 children who received tympanostomy tube surgery to treat COM with effusion or recurrent OM ([@B2]). Analysis of 324,748 SNPs revealed various SNPs on a number of chromosomes that showed suggestive or strong association with OM. The strongest of these variants was rs1110060 on chromosome 15 (p = 9.1 X 10^−7^). Replication of the findings from this genome-wide association analysis was attempted in a cohort of 652 controls and 932 affected children who also received tympanostomy tube insertion for chronic or recurrent OM ([@B2]). Of the 53 tested for replication genotyping, 4 significant SNPs (p \< 0.10) were identified. One of these 4 SNPs was rs1110060 on chromosome 15 (p = 0.072), the most significant result from the initial study, but rs10497394 on chromosome 2 was the most significant replication (initial study: p = 2.9 X 10^−5^; replication study: p = 4.7 X 10^−5^) ([@B2]). The significant SNP variants identified in this study have been added to the list of candidate genes, such as *KIF7* (in rs1110060) and *CDCA7* and *SP3* (which both border rs10497394), that require further research ([@B2]).

Another study performed a meta-analysis of two cohorts consisting of 825 cases/7,936 controls and 1,219 cases/1,067 controls from the Children's Hospital of Philadelphia (CHOP) and the Generation R Study (GenR) at Erasmus University Medical Center, the Netherlands, respectively ([@B111]). The cases were defined as individuals with AOM prior to 3 years old. The GWAS suggested a significant association between the variant rs2932989 on chromosome 6q25.3 and AOM (p = 2.15 X 10^−9^). These findings were then replicated in an independent cohort of 293 cases of AOM and 1,719 controls recruited from the Children's Hospital of Philadelphia. This SNP lies in an intergenic region near the *FNDC1* locus, so expression and methylation tests were performed to determine whether this gene could be associated with these findings. FNDC1 expression was found in multiple tissue types in mice and humans, in addition to mice ME ([@B111]). The expression of *Fndc1* was also upregulated in mouse ME after treatment with lipopolysaccharide, which induces an inflammatory response and stimulates TGF-beta, TNF-alpha, and IL-1 signaling ([@B111]). Lastly, the increase in *Fndc1* expression may be explained by experiments that show lower levels of methylation of human *FNDC1* in the SNP of interest ([@B111]).

Although these GWAS present promising results of associations between specific genetic markers and OM, GWAS also struggles with the dichotomy of high false positive rates and lower than desired power. Commonly in GWAS, the false positive rate is maintained at 5%. As a result, though, the study loses power because the p-value threshold becomes very small in order to be considered significant ([@B103]). Since the p-value is so low, there can be a number of SNPs that have associations with the trait that do not get detected because their p-value does not cross the very strict threshold. Even though there are replicable associations between some genetic variants and OM, there still remains the issue of causality. A GWAS on its own cannot explain the role of the genetic variants on the pathophysiology of OM, so studies must be carried out to further elaborate the potential mechanistic involvement of these genes.

Genetics and the Microbiome {#s1_6}
---------------------------

The composition and diversity of the microbiome, as well as the exogenous and endogenous factors that affect it, is notoriously difficult to study. However, high-throughput sequencing analysis techniques such as 16S rRNA and metagenomics (MGS) have contributed significantly to the field, allowing a more detailed study of microbiome composition, specific genetic loci, and disease progression ([@B108]; [@B116]; [@B62]; [@B4]). A more comprehensive study is valuable in light of the growing understanding of how the microbiome can either prevent or foster infectious, metabolic, inflammatory, atopic, and neurological disease through predominantly immuno-modulatory processes ([@B107]; [@B5]; [@B50]; [@B70]; [@B71]). Of note, these advancements have been facilitated by the development of microbial genome-wide association studies (mGWAS) techniques to probe the genome for loci directly influencing bacterial populations. mGWAS studies have already identified hundreds of microbial quantitative trait loci (mbQTLs) associated with alpha-diversity, beta-diversity, and abundance of particular taxonomic groups and have mapped them to polymorphisms related to mucosal immunity and metabolic processes ([@B41]; [@B15]; [@B109]; [@B114]; [@B44]; [@B62]). For example, innate immune factors such as C-type lectins, toll-like receptor (TLR) regulators including *Irak2*, and NOD-like receptors (*NOD1/NOD2*) have all been shown to affect microbial environment, while genes such as *FUT2, LCT, CARD9* have linked the host and microbiota metabolism, all of which carry implications for disease susceptibility, progression, and treatment ([@B12]; [@B64]; [@B62]).

In an attempt to extricate the environmental impact from that of a host's genome, a study reviewed mGWAS studies and methodologies and reports that mGWAS's earliest use helped identify 83 microbiome-loci associations, with follow-up studies especially supporting the discovered link between the *LCT* lactase gene and *Bifidobacterium* ([@B12]; [@B115]). Meanwhile, other studies demonstrated that 10.43% of microbiome variability (beta-diversity) between individuals can be attributed to 42 genetic loci, and that microbial diversity is particularly affected by the *VDR* (vitamin D receptor) gene ([@B114]; [@B44]). However, the majority of these existing mGWAS studies analyze gut microbiota, thereby limiting the direct application to the OM field. One of the only mGWAS studies exploring the composition of the nasal vestibule and NP microbiome was performed using 16S rRNA methods to compare a small, 144-person cohort with the alpha diversity, beta diversity, and relative abundance of bacterial taxa ([@B48]). The study identified 37 significant associations (mbQTLs) out of 148,653 genetic variants (q \< 0.05), the most significant of which linked *Dermacoccus* and the variant rs117042385 located upstream of terminal differentiation induced non-coding RNA, a non-coding RNA binding to the mRNA of *PGLYRP3* encoding a known antimicrobial protein important for epidermal differentiation ([@B48]). Importantly, the study also found a significant association between shared genetics and similar microbiome composition even after controlling for a shared household environment. Igartua et al. therefore was able to establish an association between genes, microbial populations in the upper airways, and innate mucosal immunity, thereby encouraging the further use of this new technology to the study of OM and other upper respiratory tract infections.

It is important to note some limitations of these new contributions. The conflicting results from analyses of the same data sets have been reported, though this has been ascribed to differences in statistical methods and significance cutoffs. Also, much like the limitations introduced by GWAS studies, associations identified by mGWAS are often weak at best, spread out across the genome, and therefore impose a comparatively insignificant effect. Finally, the ever-changing nature of the microbiome---a bacterial population susceptible to both short- and long-term changes influenced by diet, transient infections, and a slew of other behavioral variations of the host---complicates reproducibility of data. Therefore, carefully designed studies are needed in both the OM and the gastrointestinal fields in order to clarify links between a fixed, heritable genome to a variable as dynamic as the microbiome.

Otitis Media and the Microbiome {#s1_7}
-------------------------------

The microbiome has been implicated in the pathogenesis of OM, primarily in its role as an immunomodulator and as a competitor against invading bacteria seeking both nutrients and space. A number of studies have determined alteration in microbiome profile in OM prone individuals ([**Table 4**](#T4){ref-type="table"}). As mentioned before, the microbiome may carefully modulate host inflammatory processes through intricate cross talk between immune cells and the resident microbiota ([@B102]). Effective communication between host commensals and host immune cells is essential for both dampening inflammatory cascades when not required and promoting immune responses against invading pathogens threaten stability. The composition and integrity of the microbiome is therefore a key factor in OM pathogenesis, and next-generation sequencing technologies have allowed us to better study gene-environment interactions at this microscopic level. Herein we explore the association between both the NP and ME microbiota and their relationship with invasive, OM-causing pathogens.

###### 

A summary of studies determining microbiome of upper respiratory tract in individuals susceptible to otitis media.

  Sample type                                        Age of subjects        Sample size                                                                       Results                                                                                                                                                                      References
  -------------------------------------------------- ---------------------- --------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------
  MEF, NP swab, adenoid swab                         3--10 years            11 indigenous children with OME                                                   *- Alloiococcus, Haemophilus, Streptococcus, Moraxella*                                                                                                                      [@B51]
  Nasal aspirates                                    2--12 months           234 infants                                                                       \- *Moraxella, Streptococcus, Haemophilus*                                                                                                                                   [@B105]
  MEF, adenoid swab                                  1--12 years            23 children with COME, 10 children without COME with respiratory surgery          \- *Alloiococcus* inversely related to *Haemophilus* - Abundance of *Alloiococcus otitidis* and *Staphylococcus* in MEF                                                      [@B24]
  ME and mastoid swab                                6 months--87 years     46 children/adults with COM                                                       *- Haemophilus, Staphylococcus, Alloiococcus*                                                                                                                                [@B81]
  MEF and external auditory canal lavage             1--14 years            18 children with OME                                                              \- Predominance of *A. otitidis* and *Haemophilus* in MEF - Abundance of *A. otitidis* and *Staphylococcus* in ear canal                                                     [@B25]
  MEF                                                5 months--2.5 years    79 children with AOM                                                              \- Predominance of *S. pneumoniae*, *Haemophilus influenza*, and *Moraxella catarrhalis* - *A. otitidis, Turicella otitidis*, and *Staphylococcus auricularis*               [@B101]
  NP swab                                            \<12 months            65 children with AOM; 74 children without AOM                                     \- *Staphylococcus* and *Sphingobium* associated with decreased risk of AOM development - Infants having AOM showed reduction in numbers of *Corynebacterium*                [@B31]
  MEF                                                3 months--14.6 years   55 children with COME                                                             *- Haemophilus, Moraxella, Turicella*                                                                                                                                        [@B61]
  MEF and NP swab                                    \<12 years             9 children with gastroesophageal reflux-associated OM; 21 children with OM only   \- *Alloiococcus* and *Turicella* in MEF - *Haemophilus* and *Streptococcus* detected in MEF if also present in NP -No difference between reflux and non-reflux microbiota   [@B13]
  MEF and ME aspirates, ear canal swab, nasal swab   0--60 months           93 children with rAOM and 103 healthy controls                                    *- Haemophilus, Turicella, Alloiococcus, Staphylococcus*                                                                                                                     [@B67]
  MEF (otorrhea) and NP swab                         \<5 years              94 children with AOM+ grommets                                                    \- MEF had less microbial diversity than nasopharynx - There was an abundance of *Corynebacterium* and *Dolosigranulum*                                                      [@B75]
  NP adenoid swabs, palatine tonsillar swabs         15--65 years           14 adults with tonsil/adenoid hyperplasia; 14 adults with secretory OM            \- *S. pneumoniae*, *H. influenzae*, and *M. catarrhalis* exclusively in adenoids                                                                                            [@B36]
  ME, adenoid, and tonsil swab                       2--10 years            10 children with OME                                                              *- Fusobacterium, Haemophilus, Neisseria, Porphyromonas*                                                                                                                     [@B52]

Microbiome of the Nasopharynx {#s1_8}
-----------------------------

Microbiome ecosystems are highly specific to their immediate environment, and their composition can vary widely depending on their anatomic location within the host. For this reason, studies have repeatedly uncovered distinct resident microbiota compositions in the gut, upper respiratory tract, NP, and both the middle as well as the inner ear ([@B28]). However, AOM research often cites the first step of pathogenesis as bacterial colonization and/or viral disturbance of the NP, from which the disease eventually progresses through the Eustachian tube to the ear. Animal studies have also demonstrated this time course, with initial inoculation of bacteria in the NP followed by eventual migration to the ME, where they may persist for days, weeks, and even months ([@B33]; [@B32]; [@B97]; [@B35]). Thus, analysis of both the ME and NP microbiota is essential for obtaining a comprehensive understanding of the host-pathogen interactions leading to OM development. However, obtaining nasopharyngeal swab samples is often easier, cheaper, and less invasive than samples from the ME. Therefore, the nasopharyngeal microbiome has been more extensively studied than the ME microbiome.

The various morphologies and presentations of OM disease \[AOM, recurrent AOM (rAOM), CSOM, OME, and/or COM\] is about as varied and dynamic as the bacterial, viral, and fungal microorganisms that contribute to OM pathogenesis. However, the research has well-established the link between rAOM and the major otopathogens *S. pneumoniae*, non-typeable *Haemophilus influenza* (NTHi), and *M. catarrhalis*, and these species are consistently found at higher levels of the NP in studies comparing the microbiota of rAOM and COME cases *versus* healthy controls ([@B67]; [@B112]). Yet the presence of these same organisms, albeit at lower levels, in the controls suggest their potential role as endogenous pathobionts even in the absence of disease. NTHi was found to be the most abundant of three otopathogens in the ME with 18.5% of ME reads attributable to this species, though NTHi was still more abundant in the NP than the ME of rAOM cases. A study sequencing ME fluids/rinses, ear canal swabs, and NP using 16S rRNA observed that *Neisseria* (10.9% RA) was associated with cases of AOM specifically, while *Gemella* (3.2% RA), *Porphyromonas* (3.6% RA), *Alloprevotella* (2.4% RA), and *Fusobacterium* (2.7% RA) were also present in cases but absent (\<0.3% RA) in the NP of healthy controls ([@B67]). Taken together, the unique presence of these bacteria in rAOM cases has demonstrated an increased level of microbiota diversity in cases compared to healthy controls.

This finding is somewhat controversial, as many other studies have instead shown increased diversity in healthy controls compared to OM cases, suggesting increased bacterial diversity as a protective factor against invading pathogenic bacteria. For example, one recent study compared the NP microbiota of 3 to 4-year-old patients undergoing tympanostomy for COME and found overall microbiota diversity to be decreased in cases compared to controls, as measured by both a lower Shannon diversity index as well as cluster analyses showing an increased number of profiles dominated by one spp. in the case compared to the control group ([@B112]). However, the group's analysis still found greater levels of standard otopathogens in cases, as well as a greater level of expected commensal species such as a-hemolytic *Streptococci* and *Lactococci* in controls ([@B112]). The discrepancy in microbial diversity results may be attributable to the differences in disease processes between acute COM (aCOM) and COME, as the pathogenesis of COME distinctly occurs when bacteria in the biofilm state trigger and maintain a mucoid or serous inflammatory effusion.

Nevertheless, diversity analyses warrant future study, as only about half of all existing studies comparing microbiome diversity between AOM cases *versus* control samples have also found diversity to be higher in healthy controls. Currently, alterations in microbiome diversity are generally attributed to antibiotic use. Studies have explored how microbiota populations are near-permanently altered following the administration and completion of antibiotic regimens, with single opportunistic pathogens initially dominating but new pathogens establishing with time ([@B55]). Of note, all current data in the literature are acquired from cross-sectional cohort studies involving diseased and healthy populations; therefore, the temporality of the association cannot be empirically established. Other than chronic antibiotic use, alternative hypotheses to explain the link between increased microbial diversity and increased incidence of disease include the role of synergism in polymicrobial etiologies of OM. Animal-model studies utilizing bacterial and viral co-infections have been shown to significantly increase the incidence of bacterial OM. For example, recent studies demonstrate that the presence of different bacteria not only affects the rates and burden of nasopharyngeal colonization but can also enhance the incidence and severity of OM ([@B60]). Other studies have also noted that *M. catarrhalis* is more likely to be observed within mixed bacterial observations than isolated alone, and that this polymicrobial environment can affect the incidence of *S. pneumoniae* OM ([@B60]; [@B87]).

As OM disease more commonly affects pediatric populations, studies aiming to discern the distinct microbiome of children have helped uncover differences in the microbiota of healthy children *versus* those suffering from respiratory disease. For example, a prospective birth cohort study featuring 1,616 samples from healthy children and 1,423 samples from children with respiratory disease highlighted microbiome profile groups dominated by *Haemophilus*, *Streptococcus*, *Moraxella*, *Staphylococcus*, *Corynebacterium*, and *Alloiococcus* in 91% of samples ([@B65]). Importantly, the study noted increased abundances of *Haemophilus* (OR 3.9, p58.4x10−16), *Streptococcus* (OR 3.8, p58.9x10−18), and *Moraxella* (OR 2.1, p53.4x10−12) within the context of disease, while *Staphylococcus*, *Corynebacterium*, and *Alloiococcus* profiles were inversely correlated with disease (OR 0.22/p = 52.5x10−4, OR 0.49/p = 53.8x10−9, and OR 0.25/p = 53.7x10−17, respectively). Meanwhile, an elegant case-control study performed in the Netherlands found similar microbiome compositions within the lower respiratory tract and the NP of children, while also demonstrating that microbial profiles dominated by *H. influenzae/haemolyticus* and *S. pneumoniae* were associated with disease ([@B76]). The study also identified the importance of a combined classification model (bacterial microbiome, viral microbiome, and external factors such as antibiotic use and breastfeeding) in reliably predicting clinical disease, thereby stressing the multifactorial nature of disease ([@B76]).

*Dolosigranulum and Corynebacterium*: The Discovery and Role of Protective Bacteria {#s1_9}
-----------------------------------------------------------------------------------

While the comparison of NP microbiota generally highlights the unique presence of bacterial species in AOM cases rather than controls, two species of bacteria have instead emerged in increased abundance within the NP microbiome of healthy volunteers. The increased relative abundance of *Dolosigranulum* (16.34% case RA/1.86% control RA) and *Corynebacterium* (13.34% case RA/1.63% control RA) suggests the potential protective role of these bacteria against competing pathological bacteria seeking space and nutrients within the respiratory tract ecosystem ([@B67]). The two species were found to correlate together, thereby suggesting a symbiotic relationship potentially mediated by *Dolosigranulum'*s production of lactic acid into the environment. These findings are supported by previous reports of *Dolosigranulum* and *Corynebacterium* predominating the NP of both healthy adults and children, their association with a decreased risk of OM/AOM diagnosis or pneumococcal colonization, and a shorter duration of otorrhea ([@B69]; [@B84]; [@B14]; [@B31]; [@B75]). Interestingly, other studies have linked increased *Dolosigranulum* and *Corynebacterium* levels with both breastfeeding and vaginal (compared to *Cesarean*) deliveries, thereby suggesting a mechanism to explain the reported link between breastfeeding and OM resistance ([@B10]; [@B11]).

As described previously, however, the diminished presence of these species in rAOM case cohorts may instead be attributed to rAOM patients' heightened exposure to long-term antibiotics, and studies have indeed found *Dolosigranulum* and *Corynebacterium* relatively depleted in patients with recent history of children using antibiotics ([@B84]). Antibiotic treatments not only disrupt the host microbiome by temporarily reducing certain bacterial populations, but are also capable of inducing long-term dysbiosis, leaving hosts susceptible to infection as well as atopic and inflammatory diseases ([@B38]). Despite this, some experiments have attempted to identify a causal link between the abundance of these two species and the health of the NP. One study uncovered a mechanism in which *Corynebacterium* species *Corynebacterium accolens* was able to utilize triacylglycerols found on the human skin to assemble free fatty acids that inhibited growth of S. pneumoniae ([@B14]). Another report found *Corynebacteria* to eradicate *S. aureus* in healthy nasopharynges of adults, and yet another demonstrated how the introduction of *Corynebacteria* helped mice resist both respiratory syncytial virus and secondary pneumococcal infection, presumably through host immune modulation ([@B110]; [@B53]). Preliminary *in vitro* experiments show multiple strains of *Corynebacteria* inhibiting growth of *M. catarrhalis*, and though the mechanism is still unclear, it appears more a result of resource competition than particular bactericidal activity ([@B68]). The potential of these two species as protection against OM-causing bacteria certainly warrants further exploration, especially in light of the potential to develop novel probiotic therapies that would reduce antibiotic use. Other species demonstrating a potential clinical benefit, such as *Haemophilus haemolyticus* and *Streptococcus salivarius*, also present the opportunity for further therapeutic development ([@B77]; [@B88]). Future research should incorporate *in vivo* models to incorporate relevant host immune factors, address the impact of environmental factors that modulate host-pathogen interaction (pH, lactic acid, etc.), as well as clinical studies that control for past antibiotic exposure.

Middle Ear Microbiome {#s1_10}
---------------------

The use of nasopharyngeal washes and/or swabs as a less invasive methodical approach for the analysis of host microbiota has produced an abundance of NP microbiome analyses. Meanwhile, studies involving the extraction of ME samples are rare. One study attempting to address this discrepancy by obtaining ME saline washes and ME fluids of children undergoing grommet insertion for rAOM ([@B67]). Using 16S rRNA sequencing methods, researchers identified *Alloiococcus otitidis*, *Turicella otitidis*, and *Staphylococcus* spp. as uniquely present in the ME of patients undergoing grommet insertion for severe rAOM diagnoses. The absence of these species in nasopharyngeal swab samples also obtained from the same patients suggests these species' role as normal auricle flora and/or as standard ME pathogens in cases of OM ([@B67]). The standard otopathogens *S. pneumoniae*, NTHi, and *M. catarrhalis* were found to be present in the ME of rAOM cases, albeit at lower levels than in the NP, and also in lower levels than the standard ME pathogens previously described. However, their presence in the ME suggests bacterial migratory patterns originating in the oropharynx and extending through the Eustachian tube and into the ME, which is consistent with known OM pathogenesis. Finally, ME diversity was found to be lower than NP diversity in case samples, further establishing the NP's role as a robust reservoir for microorganisms in both the presence and absence of disease ([@B67]).

### Genetics, The Microbiome, and Otitis Media {#s1_10_1}

As previously described, a healthy microbiome is dependent on effective communication between host commensals and host immune systems, with microbiome composition and diversity in part determined by the host genome. Therefore, genetic defects affecting key biomolecular messengers/signals within this network of crosstalk can have profound effects on the integrity of this balance and therefore the microbiome itself. Within the specific context of OM pathogenesis, researchers have discovered a candidate gene that seems to shape micro-environments favoring particular groups of OM pathobionts. A rare duplication variant of *A2ML1* (α2-macroglobulin-like 1), a gene encoding a middle-ear specific protease inhibitor, has been identified to confer an increased susceptibility to OM ([@B94]). The study incorporated samples from a 250-member intermarried indigenous Filipino community with a 49.6% prevalence of OM, which ultimately identified the *A2ML1* duplication c.2478_2485dupGGCTAAAT (p.Ser829Trpfs\*9) as co-segregating with OM with a logarithm of odds (LOD) of 7.5. The study also compared these findings with 123 otitis-prone and 118 non-otitis prone children from the University of Texas Medical Branch (UTMB). Within the Texas cohort, 3 of the 123 otitis-prone children were found to have the same A2ML1 variant, all of whom reported early-onset severe OM that ultimately required tympanostomy tube insertion surgeries.

While this initial study identified the candidate gene and therefore suggested the genetic link to OM susceptibility, follow-up studies uncovered the host microbiome composition as an essential mediator of the association. Using 16S rRNA gene sequencing for microbiome analysis of outer and ME, samples from carriers of the *A2ML1* variant were found to have higher levels of *Fusobacterium, Porphyromonas, Peptostreptococcus, Parvimonas*, and *Bacteroides* compared to wild-type COM cases, and variant carriers also demonstrated an increased alpha-diversity *via* mean Shannon diversity index ([@B95]). Meanwhile, microbiota from wild-type cases were more likely to feature well-known otopathogens such as *Alloiococcus*, *Staphylococcus, Proteus*, and *Haemophilus*. It is important to note that study limitations were characterized by issues of statistical significance due to small sample sizes, as the study cohort included only 16 indigenous Filipino patients, 11 of whom carry the *A2ML1* variant. However, these studies are the first of their kind in that they specifically apply the genome-microbiome interaction to OM disease susceptibility, offering exciting new avenues for further exploration in our field especially.

Conclusion and Future Directions {#s2}
================================

Genetic predisposition to OM has been elucidated through twin studies, linkage association studies, candidate gene approaches, and genome-wide association studies, but further research is necessary to precisely understand the genetic etiology and determine which genes are at play. Through these studies, a number of genes and SNPs have been implicated, including *FBXO11, TGIF1, FUT2, CAPN14, GALNT14, KIF7, CDCA7, SP3*, and *FNDC1*, yet replication of these results has been unsuccessful. One major issue with replication of genetic findings is that it is incredibly difficult to find cohorts with the exact same clinical phenotype for OM. Further, some cohorts focus on healthy *versus* AOM, others focus on acute OM *vs.* recurrent OM/COME. In addition to these studies, a growing body of research incorporating bioinformatical analysis of host microbiota is beginning to identify how these particular genes influence OM susceptibility through mediation of the host microbiota, such as the *A2ML1* variant's association with *Fusobacterium* and *Bacteroides* anaerobic bacteria within the NP of chronic AOM patients. Meanwhile, studies are comparing resident host microbiota of healthy controls *versus* COM cases within both the NP and the ME/ear canal. While data from these studies reinforce conclusions regarding *S. pneumoniae*, NTHi, and *M. catarrhalis* as primary otopathogens, they also found these three species at higher levels in the NP than the ME, which was instead predominantly colonized with *Staphylococcus* spp., *A. otitidis*, and *T. otitidis*. However, these studies demonstrate the highest level of bacterial diversity in the NP of OM cases when compared to NP and ME bacterial populations within both case and control patients. These findings challenge a series of studies that have found higher bacterial diversity to be associated with healthy microbiota compared to COME microbiota, though the controversy reinforces the need to establish temporality in future studies due to antibiotic use as a potential confounding variable. These studies also have identified higher levels of *Dolosigranulum* and *Corynebacterium* in healthy control NP microbiota, thereby suggesting a potential protective effect that may be harnessed in the form of novel probiotic therapies. This hypothesis must be tested within the context of longitudinal studies, as *Dolosigranulum* and *Corynebacterium* may simply be more susceptible to long-term antibiotic use more prevalent in the aCOM case group. However, as studies highlighting the gene-microbiome interactions are especially new and offer the greatest potential in the coming years, we anticipate the expansion of new insights that may be applicable to the development of novel probiotic therapies for OM.
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